Type 2 diabetes patients with chronic kidney diseases can survive longer with metformin
An observational and national cohort study done by researchers shows 36 percent decrease in the risk of death or mortality among type 2 diabetes (T2D) patients with chronic kidney diseases (CKD) by starting metformin treatment compared with those patients starting with sulfonylurea treatment. This means diabetic patients with chronic kidney diseases (also called chronic renal failure CRF) may survive longer with metformin drug.
Researchers have conducted studies among 175,296 veterans. All individuals have received at least one-year treatment from the Veterans Health Administration (VHA), a part of the United States Department of Veterans Affairs (VA). After receiving treatment from VHA, all of them were under monotherapy (usage of a single drug) for the treatment of type 2 diabetes with either sulfonylurea or metformin between 2004 and 2009. The study findings show.
FDA guidance advises metformin drug initiation among type 2 diabetes patients with estimated glomerular filtration rate (eGFR) of 45 to 59
Lead author of the study was James S. Floyd, MD, the University of Washington, Seattle, the United States. The study findings were published November 27, 2017, in the Journal of General Internal Medicine. Title of the article was "Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.